Abstract-In patients with drug-resistant hypertension, chronic electric stimulation of the carotid baroreflex is an investigational therapy for blood pressure reduction. We hypothesized that changes in cardiac autonomic regulation can be demonstrated in response to chronic baroreceptor stimulation, and we analyzed the correlation with blood pressure changes. Twenty-one patients with drug-resistant hypertension were prospectively included in a substudy of the Device Based Therapy in Hypertension Trial. Heart rate variability and heart rate turbulence were analyzed using 24-hour ECG.Recordings were obtained 1 month after device implantation with the stimulator off and after 3 months of chronic electric stimulation (stimulator on). Chronic baroreceptor stimulation decreased office blood pressure from 185Ϯ31/ 109Ϯ24 mm Hg to 154Ϯ23/95Ϯ16 mm Hg (PϽ0.0001/Pϭ0.002). Mean heart rate decreased from 81Ϯ11 to 76Ϯ10 beats per minute Ϫ1 (Pϭ0.001). Heart rate variability frequency-domain parameters assessed using fast Fourier transformation (FFT; ratio of low frequency:high frequency: 2.78 versus 2.24 for off versus on; PϽ0.001) were significantly changed during stimulation of the carotid baroreceptor, and heart rate turbulence onset was significantly decreased (turbulence onset: Ϫ0.002 versus Ϫ0.015 for off versus on; Pϭ0.004). In conclusion, chronic baroreceptor stimulation causes sustained changes in heart rate variability and heart rate turbulence that are consistent with inhibition of sympathetic activity and increase of parasympathetic activity in patients with drug-resistant systemic hypertension; these changes correlate with blood pressure reduction. Whether the autonomic modulation has favorable cardiovascular effects beyond blood pressure control should be investigated in further studies. Key Words: baroreflex Ⅲ arterial hypertension Ⅲ electric baroreflex stimulation Ⅲ heart rate variability Ⅲ heart rate turbulence Ⅲ drug-resistant arterial hypertension Ⅲ cardiac autonomic system S ystemic arterial hypertension is one of the leading cardiovascular diseases in the world and a major cardiovascular risk for coronary artery disease, cerebrovascular disease, and heart and renal failure. Despite carefully assessing causes and stratifying therapeutic approaches using all of the existing antihypertensive pharmacological agents, not all hypertensive patients sufficiently respond to pharmacological treatment. Stimulation of the carotid baroreceptor (SCB) was considered several decades ago as a potential treatment for blood pressure (BP) lowering in humans. [1][2][3] The roles of carotid baroreceptors in acute regulation of BP and the acute effect of SCB are well documented. 3,4 However, whether arterial baroreceptors play a role in long-term regulation of arterial pressure is still debated, 5 and the benefit of chronic SCB as treatment of hypertension in humans is currently under investigation. Lohmeier et al 6,7 demonstrated that electric activation of the baroreflex lasting 7 days produces sustained hypotension in dogs usin...